SA
NTLA

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Intellia Therapeutics is a clinical-stage CRISPR gene-editing company developing in vivo (direct injection) and ex vivo (cell-based) therapies for genetic diseases. The company's lead program NTLA-2001 for transthyretin amyloidosis (ATTR) represents the first systemically delivered CRISPR therapeutic in human trials, with potential regulatory filings anticipated in 2026-2027. Intellia's competitive advantage lies in its lipid nanoparticle delivery platform enabling direct in vivo editing, differentiating it from ex vivo CAR-T approaches.

HealthcareGene Editing & Cell Therapy Biotechnologylow - Clinical-stage biotech with high fixed R&D costs ($250M+ annually) and minimal revenue. Operating leverage emerges only post-commercialization when manufacturing and sales infrastructure are built. Current -923% operating margin reflects pre-revenue development phase. Platform approach enables multiple programs from single technology investment, creating potential future leverage.

Business Overview

01Collaboration revenue from partnerships (Regeneron, Novartis) representing majority of current revenue
02Milestone payments tied to clinical development progress and regulatory achievements
03Future product sales from proprietary programs (currently pre-commercial, estimated 2027+ launch)

Intellia operates a dual-track model: (1) partnered programs where it receives upfront payments, development milestones, and royalties on future sales (e.g., Regeneron collaboration on hemophilia A/B), and (2) wholly-owned programs where it retains 100% economics but bears full development costs. The company's pricing power will depend on demonstrating durable gene editing with single-dose administration versus chronic therapies. Current burn rate of approximately $300M annually is funded by $650M+ cash position (6+ quarters of runway based on Q4 2025 estimates). Revenue is episodic and milestone-driven until commercial launch.

What Moves the Stock

NTLA-2001 Phase 3 ATTR amyloidosis trial data readouts and regulatory filing timelines (primary catalyst)

Clinical data from hemophilia A/B programs (partnered with Regeneron) demonstrating durability of editing

Expansion of in vivo editing platform to new indications (oncology, autoimmune) and IND filings

Partnership announcements with upfront payments and validation of technology platform

Competitive developments from CRISPR Therapeutics, Editas Medicine, Beam Therapeutics, and Verve Therapeutics

FDA guidance on gene-editing regulatory pathways and manufacturing standards

Watch on Earnings
Cash runway and quarterly burn rate (critical for pre-revenue biotech)Clinical trial enrollment rates and timeline guidance for NTLA-2001 and pipeline programsCollaboration milestone achievements and revenue recognition timingPipeline advancement (IND filings, trial initiations, dose escalations)Manufacturing scale-up progress for lipid nanoparticle delivery system

Risk Factors

Regulatory uncertainty around gene-editing therapies with limited precedent (only two approved CRISPR therapies as of 2026, both ex vivo)

Manufacturing complexity and scalability of lipid nanoparticle delivery systems for commercial production

Long-term safety monitoring requirements may extend development timelines and increase costs beyond traditional small molecules

Reimbursement uncertainty for high-cost gene therapies (likely $500K-$2M+ per patient) amid payer scrutiny

CRISPR Therapeutics and Vertex partnership advancing competing ex vivo programs with earlier commercial traction

Base editing and prime editing technologies (Beam Therapeutics, Prime Medicine) may offer superior precision and safety profiles

Large pharma in-house gene-editing capabilities reducing partnership opportunities and milestone revenue

Patent litigation risk in crowded CRISPR IP landscape (Broad Institute vs. UC Berkeley foundational patents)

Cash burn of $300M+ annually requires equity raises within 18-24 months absent partnership influx

Dilution risk from future financings at potentially unfavorable valuations if clinical setbacks occur

Current 6.21x current ratio is strong but declining as R&D expenses accelerate into Phase 3 trials

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - Clinical development timelines are independent of GDP cycles. However, capital markets conditions affect ability to raise financing for cash-intensive R&D. Biotech sector correlates with risk appetite rather than economic fundamentals. Healthcare spending on rare disease treatments is relatively recession-resistant.

Interest Rates

Rising rates negatively impact valuation through higher discount rates applied to distant cash flows (products likely 2027+ launch). Pre-revenue biotechs are duration assets with negative near-term cash flows, making them highly sensitive to risk-free rate changes. Higher rates also increase cost of capital for future equity raises needed to fund development. Fed funds rate and 10-year Treasury yields directly affect biotech sector multiples.

Credit

Minimal direct credit exposure with 0.13x debt/equity ratio and $650M+ cash position. Company relies on equity markets rather than debt financing. However, tightening credit conditions reduce institutional investor appetite for speculative biotech, affecting stock liquidity and valuation multiples.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - Attracts speculative biotech investors focused on binary clinical catalysts and platform technology potential. Recent 47% three-month return reflects momentum trading around clinical milestones. Not suitable for value or income investors given negative earnings and no dividend. Institutional ownership includes specialized healthcare funds and venture-style public market investors willing to accept 3-5 year development timelines.

high - Clinical-stage biotech with binary event risk around trial data. Stock exhibits 60%+ annualized volatility typical of pre-revenue biotechs. Single clinical readout can move stock 30-50% in either direction. Low float and institutional concentration amplify price swings. Beta likely 1.5-2.0x relative to broader market.

Key Metrics to Watch
NTLA-2001 serum TTR protein reduction levels and durability in Phase 3 ATTR trial (primary efficacy endpoint)
Factor VIII/IX expression levels in hemophilia programs and bleeding event reduction
Cash position and quarterly operating cash flow burn rate
XBI (SPDR S&P Biotech ETF) performance as sector sentiment indicator
10-year Treasury yield as proxy for biotech valuation multiples
Competitor clinical trial results and regulatory approvals in gene-editing space
Partnership deal structures and upfront payment sizes in biotech sector
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.